What question did this study set out to answer?

Evaluate the safety and preliminary efficacy of GT201 in treating advanced solid tumors.

Armored TIL GT201 Induces Tumor-Specific TCR Expansion and Antitumor Responses

View Full Paper

Ask AI

Bookmark

Evaluate the safety and preliminary efficacy of GT201 in treating advanced solid tumors.
Multi-center, open-label, single-arm clinical study
Assessment of safety according to CTCAE v5.0
Evaluation of overall response rate (ORR) and disease control rate (DCR) using RECIST v1.1
Analysis of clonal dynamics via single-cell RNA/TCR sequencing
Longitudinal tumor biopsies and blood samples were collected for multi-omics profiling.
GT201 presented a favorable safety profile with most adverse events being Grade 1-2
ORR was 58.3% with 83.3% DCR
Two complete responses and five partial responses were documented
Tumor-specific TCRs showed significant expansion in responders
Multi-omics analyses suggested that the expansion of specific TCRs correlates with clinical benefit.

No takes yet. Share an insight, caveat, or question.

Exploratory study shows GT201 enhances tumor-specific TCR expansion in advanced solid tumors, indicating potential efficacy.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark